TY - JOUR
T1 - Microglia and Central Nervous System-Associated Macrophages mdash from Origin to Disease Modulation
AU - Prinz, Marco
AU - Masuda, Takahiro
AU - Wheeler, Michael A.
AU - Quintana, Francisco J.
N1 - Funding Information:
We thank A. Dumas for critical proofreading and L. Amann for excellent figure preparations. M.P. was supported by the Sobek Foundation; the Ernst Jung Foundation, the DFG (SFB 992, SFB1160, SFB/TRR167, Reinhart Koselleck Grant, Gottfried Wilhelm Leibniz Prize); and the Ministry of Science, Research and Arts, Baden-Wuerttemberg (Sonderlinie “Neuroin-flammation”). This study was supported by the DFG under Germany’s Excellence Strategy (CIBSS – EXC-2189 – Project ID390939984). T.M. was supported by AMED (grant number JP20gm6310016), JSPS KAKENHI (20K22687), the Naito Foundation, and the KANAE Foundation for the Promotion of Medical Science. M.A.W. was supported by a K99/R00 Pathway to Independence Award from the NIH (1K99NS114111), a postdoctoral fellowship from the NIH (F32NS101790), a training grant from the NIH and Dana-Farber Cancer Institute (T32CA207201), a traveling neuroscience fellowship from the Program in Interdisciplinary Neuroscience at Brigham and Women’s Hospital, and the Women’s Brain Initiative at Brigham and Women’s Hospital. F.J.Q. was supported by the NIH (NS102807, ES02530, ES029136, AI126880), the National Multiple Sclerosis Society (RG4111A1) and the International Progressive MS Alliance (PA-1604-08459).
Funding Information:
We thank A. Dumas for critical proofreading and L. Amann for excellent figure preparations. M.P. was supported by the Sobek Foundation; the Ernst Jung Foundation, the DFG (SFB 992, SFB1160, SFB/TRR167, Reinhart Koselleck Grant, Gottfried Wilhelm Leibniz Prize); and the Ministry of Science, Research and Arts, Baden-Wuerttemberg (Sonderlinie Neuroinflammation ). This study was supported by the DFG under Germany s Excellence Strategy (CIBSS EXC-2189 Project ID390939984). T.M. was supported by AMED (grant number JP20gm6310016), JSPS KAKENHI (20K22687), the Naito Foundation, and the KANAE Foundation for the Promotion of Medical Science. M.A.W. was supported by a K99/R00 Pathway to Independence Award from the NIH (1K99NS114111), a postdoctoral fellowship from the NIH (F32NS101790), a training grant from the NIH and Dana-Farber Cancer Institute (T32CA207201), a traveling neuroscience fellowship from the Program in Interdisciplinary Neuroscience at Brigham and Women s Hospital, and the Women s Brain Initiative at Brigham and Women s Hospital. F.J.Q. was supported by the NIH (NS102807, ES02530, ES029136, AI126880), the National Multiple Sclerosis Society (RG4111A1) and the International Progressive MS Alliance (PA-1604-08459).
Publisher Copyright:
© 2021 Annual Reviews Inc.. All rights reserved.
PY - 2021/4/26
Y1 - 2021/4/26
N2 - The immune system of the central nervous system (CNS) consists primarily of innate immune cells. These are highly specialized macrophages found either in the parenchyma, called microglia, or at the CNS interfaces, such as leptomeningeal, perivascular, and choroid plexus macrophages. While they were primarily thought of as phagocytes, their function extends well beyond simple removal of cell debris during development and diseases. Brain-resident innate immune cells were found to be plastic, long-lived, and host to an outstanding number of risk genes for multiple pathologies. As a result, they are now considered the most suitable targets for modulating CNS diseases. Additionally, recent single-cell technologies enhanced our molecular understanding of their origins, fates, interactomes, and functional cell statesduring health and perturbation. Here, we review the current state of our understanding and challenges of the myeloid cell biology in the CNS and treatment options for related diseases.
AB - The immune system of the central nervous system (CNS) consists primarily of innate immune cells. These are highly specialized macrophages found either in the parenchyma, called microglia, or at the CNS interfaces, such as leptomeningeal, perivascular, and choroid plexus macrophages. While they were primarily thought of as phagocytes, their function extends well beyond simple removal of cell debris during development and diseases. Brain-resident innate immune cells were found to be plastic, long-lived, and host to an outstanding number of risk genes for multiple pathologies. As a result, they are now considered the most suitable targets for modulating CNS diseases. Additionally, recent single-cell technologies enhanced our molecular understanding of their origins, fates, interactomes, and functional cell statesduring health and perturbation. Here, we review the current state of our understanding and challenges of the myeloid cell biology in the CNS and treatment options for related diseases.
UR - http://www.scopus.com/inward/record.url?scp=85104043497&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104043497&partnerID=8YFLogxK
U2 - 10.1146/annurev-immunol-093019-110159
DO - 10.1146/annurev-immunol-093019-110159
M3 - Review article
C2 - 33556248
AN - SCOPUS:85104043497
SN - 0732-0582
VL - 39
SP - 251
EP - 277
JO - Annual Review of Immunology
JF - Annual Review of Immunology
ER -